Clinical trial · Interventional
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
NCT07472387CI-TRIAL-00105632Andro-iGlionot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma (GBM) | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sampling | Other | — | UNRESOLVED |
| saliva sampling | Other | — | UNRESOLVED |
| stool sampling | Other | — | UNRESOLVED |
| Tumor sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Glioblastoma patients
- description
- Adult men and women with GBM who are being treated in the neuro-oncology department at La Pitié-Salpêtrière Hospital.
- interventionNames
- Other: blood sampling
- Other: saliva sampling
- Other: stool sampling
- Other: Tumor sampling
Primary outcomes (1)
- measure
- Mean expression of AR, ER, and other hormone signaling pathway genes in the tumor
- timeFrame
- Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy
- description
- Expression of AR, ER, and other hormone signaling pathway genes using tumor RNA sequencing data
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥18 and ≤55 * Newly diagnosed GBM * Surgery with complete or incomplete resection * Eligible for chemoradiotherapy * No active immune disorders * Supratentorial location on MRI and no signs of meningeal dissemination * Tumor sample (taken as part of treatment) available for study (fresh frozen tissue) * Patient informed and consented to participate in the study * Affiliation with a social security system or beneficiary Exclusion Criteria: * Active infection at the time of sampling or within the previous 14 days * Active immune disorders * Known patients with low-grade glioma that has undergone anaplastic transformation * Patients treated with corticosteroids * Patients participating in interventional research * Patients under legal protection, guardianship, or conservatorship. * Pregnant or breastfeeding women * Individuals under AME
References
Publications (0)
Data not yet available
No reference posted for this study.